Phase 3 · NCT07035093
TRIUMPH-7
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
Registry record
Trial details
- Trial
- TRIUMPH-7
- ClinicalTrials.gov ID
- NCT07035093
- Indication
- Obesity, Overweight, Chronic Low Back Pain (CLBP)
- Phase
- Phase 3
- Study type
- Interventional
- Sponsor
- Eli Lilly and Company
- Enrolment
- 586
- Status
- Active, not recruiting
- Interventions
- Drug: Retatrutide; Drug: Placebo
- Comparator
- Placebo
- Eligible ages
- 18 Years – No maximum
- Locations
- 40 sites · Argentina, Canada, Poland, United States
- Study start
- 29 May 2025
- Primary completion
- 1 Sept 2027
- Study completion
- 1 Sept 2027
Verification
- Last verified
- 4 Sept 2026
- Source
- ClinicalTrials.gov
- Registry last updated
- 23 Jul 2026
Endpoints
Primary
Change from Baseline in Pain Intensity Per Numeric Rating Scale; Percent Change from Baseline in Body Weight
Secondary
Number of Participants with Reduction in Pain Intensity Per Numeric Rating Scale; Number of Participants with Reduction in Body Weight; Change in Physical Function as Measured by Patient-Reported Outcomes Measurement Information Systems (PROMIS); Change in Pain Interference as Measured by PROMIS; Change in Sleep as Measured by PROMIS; Change in Patient Reported Health Outcomes as Measured by Medical Outcomes Study 36-item Short Form Health Survey version 2 (SF-36v2); Change in Waist Circumference; Change in Biomarkers of Inflammation as Measured by Blood Test; Change in Blood Pressure; Change in Glycemic Control; Percent Change in Total Cholesterol; Percent Change in Urine Albumin-to-Creatinine Ratio (UACR)